We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01956786
Recruitment Status : Unknown
Verified July 2013 by Shenzhen Ausa Pharmed Co.,Ltd.
Recruitment status was:  Recruiting
First Posted : October 8, 2013
Last Update Posted : October 8, 2013
Sponsor:
Collaborators:
Ruijin Hospital
Second Affiliated Hospital of Nanchang University
Xuzhou Medical University
Information provided by (Responsible Party):
Shenzhen Ausa Pharmed Co.,Ltd

Brief Summary:
To evaluate the efficacy of Amlodipine-Folic Acid Tablets on reduction of blood pressure and plasma total homocysteine.

Condition or disease Intervention/treatment Phase
Essential Hypertension Drug: Amlodipine-FA tablet,low dose group Drug: Amlodipine-FA tablet,high dose group Drug: Amlodipine Phase 2 Phase 3

Detailed Description:

Traditional risk factors are estimated to account for only part of cardiovascular disease (CVD)risk. Non-traditional risk factors such as increased homocysteine concentrations are believed to be causally related to CVD. The interactive effect between hypertension and hyperhomocysteinemia on the risk of CVD has received great attention. Methylenetetrahydrofolate reductase (MTHFR)was the main regulatory enzymes for homocysteine metabolism. MTHFR converts 5,10-methylene-THF into 5-methyl-THF. Polymorphism of MTHFR C677T leads to a reduction in enzyme activity, which may lead to an increased concentration of plasma homocysteine and lower levels of serum folate, particularly in those with low folate intake. Enalapril Maleate-Folate Tablets, known to reduce both blood pressure and serum homocysteine and thereby preventing stroke, was found to have adverse events, such as cough, called ACEI-intolerance in some patients.

In the present study, we sought to assess:(1)the efficacy and safety of Amlodipine-Folic Acid Tablets in lowing blood pressure and homocysteine in patients with mild to moderate hypertension, hyperhomocysteinemia (hcy≥10μmol/L)and ACEI intolerance;(2)whether the blood pressure and homocysteine-lowing efficacy of Amlodipine-Folic Acid Tablets can be modified by individual MTHFR C677T polymorphisms.

In all, about 540 patients with mild to moderate hypertension, hyperhomocysteinemia and ACEI intolerance will be enrolled in this trial. Eligible subjects are randomly and double-blindly assigned to one of the three treatment groups:1)amlodipine tablet(5mg,control group);2)amlodipine-folic acid tablet(5mg amlodipine combined with 0.4mg of folic acid,low FA group);or 3)amlodipine-folic acid tablet (5mg amlodipine combined with 0.8mg of folic acid,high FA group),once daily for 8 weeks.

The allocation of participants was programmed by an independent statistical coordinating center,encrypted,and sent to each study center.Tablet containers were labeled only with the name of the trial and the allocated concealment number.The participants,care partners,and all staff directly involved in the trial were blinded to interventions during the period of the trial.

Demographic and clinical information were obtained at baseline. Blood pressure was examined at baseline and every two weeks for a total period of 8 weeks. Blood homocysteine and folate concentrations were examined at baseline and at 4th、8th weeks of the trial. MTHFR C677T genotypes were determined for each study subject.

All analyses will be performed according to the principle of intention to treat.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 540 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine in Patients With Mild to Moderate Hypertension, Hyperhomocysteinemia and Angiotension-Converting Enzyme Inhibitor Intolerance
Study Start Date : September 2013
Estimated Primary Completion Date : December 2013
Estimated Study Completion Date : February 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Amlodipine
5mg amlodipine,once daily for 8 weeks
Drug: Amlodipine
5mg amlodipine,once daily
Other Name: control

Experimental: Amlodipine-FA tablet,low dose group
5mg amlodipine combined with 0.4mg of folic acid (FA),once daily for 8 weeks.
Drug: Amlodipine-FA tablet,low dose group
5mg amlodipine combined with 0.4mg folic acid,once daily (Low-dose group)
Other Name: low dose

Experimental: Amlodipine-FA tablet,high dose group
5mg amlodipine combined with 0.8mg of folic acid (FA),once daily for 8 weeks.
Drug: Amlodipine-FA tablet,high dose group
5mg amlodipine combined with 0.8mg folic acid,once daily (High-dose group)
Other Name: high dose




Primary Outcome Measures :
  1. Combined effective rate of blood pressure and plasma homocysteine reduction [ Time Frame: Blood pressure was examined at baseline and every 2 weeks for a total period of 8 weeks.Blood homocysteine concentrations were measured at baseline and at 4th and 8th week of the trial. ]

Secondary Outcome Measures :
  1. Blood pressure reduction or plasma homocysteine reduction [ Time Frame: Blood pressure was examined at baseline and every 2 weeks of a total period of 8 weeks. Blood homocysteine concentrations was examined at baseline and at 4th and 8th week of the trial. ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Aged 18-75 years;
  2. Sedentary systolic blood pressure between 140 mmHg and 180 mmHg, and/or sedentary diastolic blood pressure between 90 mmHg and 110 mmHg;
  3. Plasma homocysteine ≥ 10μmol/L;
  4. ACEI-intolerance
  5. Signed the written informed consent.

Exclusion Criteria:

  1. Pregnant women or women within lactation period;
  2. Hypersensitive to Calcium Channel Blocker (CCB) or folic acid;
  3. Easily hypersensitiveness;
  4. Diagnosed secondary hypertension or skeptical secondary hypertension;
  5. Severe hypertension (sedentary systolic blood pressure greater than or equal to 180 mmHg and/or sedentary diastolic blood pressure greater than or equal to 110 mmHg)
  6. Severe diseases:

    1. Cardiovascular system:Diagnosed cardia insufficiency (New York Health Association [NYHA] Ⅲ level and higher);Hypertrophic obstructive cardiomyopathy (HOCM);Clinical significantly Valvular Disease of the Heart (VDH);Acute coronary syndrome or coronary artery interventional therapy or coronary artery bypass graft within three months;Severe arrhythmia such as atrial flutter, atrial fibrillation, atrioventricular block above Ⅱlevel, et al;
    2. Alimentary system:Active virus hepatitis;Any of alanine aminotransferase (ALT), aspartate aminotransferase (AST), galactosylhydroxylysyl glucosyltransferase (GGT), alkaline phosphatase (ALP), total bilirubin (TBIL), Direct Bilirubin (DB) was above 2 times of it's normal value upper limit, albumin (ALB) greater than 30 g/L;Stomach bulk resect and gastrojejunostomy;Stomach intestine malabsorption;
    3. Urinary system:Serum creatinine greater than or equal to 200 mmol/L;Diagnosed stenosis of renal artery, solitary kidney;Renal transplantation;
    4. Endocrine system:Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus (fasting glucose greater than or equal to 11.1 mmol/L);Diagnosed and uncontrolled hyperthyrosis;
    5. Respiratory system:Pulmonary Heart Disease;Chronic Obstructive Pulmonary Disease(COPD);
    6. Neuropsychiatric system:Transient Ischemia Attach (TIA) or stroke within 3 months;Severe peripheral nerve or vegetative nerve functional disturbance; Psyche or nervous system dysfunction;Drugs or alcohol dependence;
    7. Others:Malignant tumor, malnutrition, haematogenesis dysfunction, et al;
  7. Obviously abnormal laboratory examination or signs;
  8. Taking other antihypertensive drugs and unwilling to stop;
  9. Taking folic acid or other Vitamin B groups and unwilling to stop;
  10. Ever to participant in any drug trial not yet approved within 4 weeks before the first visit.

    -


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01956786


Locations
Layout table for location information
China, Jiangsu
The Affiliated Hospital of Xuzhou Medical College Not yet recruiting
Xuzhou, Jiangsu, China, 221006
Contact: Wang Zhirong, MD    86-0516-85802111    xzzrw@163.com   
Principal Investigator: Wang Zhirong, MD         
China, Jiangxi
The Second Affiliated Hospital of Nanchang University Recruiting
Nanchang, Jiangxi, China, 330006
Contact: Cheng Xiaoshu, MD    86-791-6268844    xiaoshumenfan@126.com   
Principal Investigator: Cheng Xiaoshu, MD         
China, Shanghai
Ruijin Hospital, Shanghai Jiao Tong Univesity Recruiting
Shanghai, Shanghai, China, 310000
Contact: Wang Jiguang, MD    86-021-64370045    jiguangw@gmail.com   
Principal Investigator: Wang Jiguang, MD         
Sponsors and Collaborators
Shenzhen Ausa Pharmed Co.,Ltd
Ruijin Hospital
Second Affiliated Hospital of Nanchang University
Xuzhou Medical University
Investigators
Layout table for investigator information
Principal Investigator: Wang Jiguang, MD Ruijin Hospital, Shanghai Jiao Tong University
Layout table for additonal information
Responsible Party: Shenzhen Ausa Pharmed Co.,Ltd
ClinicalTrials.gov Identifier: NCT01956786    
Other Study ID Numbers: Ausa-Amlodipine B
First Posted: October 8, 2013    Key Record Dates
Last Update Posted: October 8, 2013
Last Verified: July 2013
Keywords provided by Shenzhen Ausa Pharmed Co.,Ltd:
Amlodipine
Folic Acid
Homocysteine
Blood Pressure
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Essential Hypertension
Vascular Diseases
Cardiovascular Diseases
Amlodipine
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Vasodilator Agents